Overview

A Study of LM-24C5 For Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

LaNova Medicines Limited